According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
2don MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...
TipRanks on MSN
CRISPR Therapeutics Reports Q3 2025 Financial Results
Crispr Therapeutics ( ($CRSP) ) has released its Q3 earnings. Here is a breakdown of the information Crispr Therapeutics presented to its ...
Clustered regularly interspaced palindromic repeats(CRISPR) gene editing, known for its precision, is revolutionizing tumor research and treatment. This article covers the evolution of the CRISPR ...
CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...
Jarome and his team found that aging disrupts K63 polyubiquitination in two distinct areas of the brain. In the hippocampus, ...
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback